Protocol Ledger

NCT07622186 · Phase II · RECRUITING

A Study of SKB571 Combination Therapy in Participants With Non-Small Cell Lung Cancer (NSCLC)

Interventional Phase II clinical trial protocol NCT07622186 sponsored by Sichuan Kelun-Biotech Biopharmaceutical Co in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-07-15 Enrollment: 150 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07622186
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)150 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07622186
Protocol FieldVerified Registry Value
NCT IdentifierNCT07622186
Consolidated Lead SponsorSichuan Kelun-Biotech Biopharmaceutical Co
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment150 participants (ESTIMATED)
Registered Start Date2026-07-15
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI